Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Hamad Alam
Rectal Adenocarcinoma
New Delhi
Hamad’s struggle reached a terrifying peak in 2018 while traveling back to Delhi from a cou…
Shilipi
Acute Recurrent Pancreatitis
Kotdwar, Uttarakhand.
Shilpi’s struggle began suddenly during her 10th-grade school break, when she felt a sharp …
Anurag Goyal
Investment Banker
New Delhi
Anurag’s struggle began suddenly in the midnight of September 2010, when he experienced exc…
Sumit Kumar
Pancreas Divisum with secondary Chronic Pancreatitis
Dehradun, Uttarakhand
Sumit suffered from Pancreas Divisum, a congenital anomaly where the two pancreatic ducts (the ve…
Aviral Saxena
Chronic Pancreatitis with Secondary Diabetes
Dehradun, Uttarakhand
Aviral’s journey began in November 2022 while he was actively working as a freelancer. The …
Rajeev Sharma
Chronic Pancreatitis
Dehradun, Uttarakhand
Rajeev’s journey began with mild symptoms in 2009, potentially following a physical encount…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Changing Demography of Pancreatitis Patients in India -A Hospital Based Study
Pancreatitis is rising globally, with major risk factors including alcohol, tobacco, and family history. A study of 800 patients in North India found higher incidences among non-alcoholic, non-tobacco users, and those with no family history. The disease mostly affected men (4.6:1) aged 19-45, particularly in the service class and students. Further research is needed to explore its causes and extent in the region.
CA19-9 LOWERING EFFECT OF AN AYURVEDIC MINERAL COMPLEX PREPARED USING COPPER, MERCURY AND SULPHUR
Rasa Shastra, an Ayurvedic practice using metals and minerals, has shown that Ayurvedic Mineral Complex (AMC) helps reduce elevated CA19-9 levels in pancreatitis patients. This suggests AMC could be explored as a preventive therapy for pancreatic cancer.
Case studies on prophylactic ayurvedic therapy in migraine patients
Ayurvedic treatment has shown effectiveness in managing migraines. A protocol (ATP) with herbo-mineral formulations, regular meals, and sleep reduced migraine frequency and intensity in a study of nine patients. Five reported significant improvement after 120 days, with no serious side effects. Ongoing research is further validating the findings.
Anti-Inflammatory Properties of a Processed Copper Complex in L-Arginine Induced Pancreatitis-Two Experimental Studies
Recurrent Acute/Chronic Pancreatitis (RA/CP) is a progressive pancreatic inflammation, often with unclear causes. An Ayurvedic Mineral Complex (AMC) showed promise in reducing exacerbations and hospitalizations in pancreatitis patients. In a rat model, AMC was well tolerated, reduced oxidative stress and inflammation, and protected the pancreas at doses of 25 mg/kg and 19 mg/kg.
Immunomodulatory Effects of a Herbo-Mineral Ayurvedic Formulation in Experimental Models
IMMBO, a herbo-mineral Ayurvedic formulation, shows promise as an immune-modulator in immunosuppressed rats. It enhances immunity, blocks histamine release, and modulates key molecules like TNF-α and NF-κB, offering potential for allergic and immune-related disorders.
Ayurvedic treatment protocol in the management of pancreatitis: A nonrandomized observational study
A North Indian clinic treated 1750 recurrent pancreatitis patients (1997–2023) with an ayurvedic Herbo-Mineral Formulation (HMF). Among 916 completing 1-year treatment, attacks reduced by 93%, hospitalizations by 97%, with no adverse effects. Long-term remission supports further clinical trials.